Maxim Group Downgrades Synaptogenix to Hold

Maxim Group analyst Jason McCarthy downgrades Synaptogenix (NASDAQ:SNPX) from Buy to Hold.

Maxim Group analyst Jason McCarthy downgrades Synaptogenix (NASDAQ:SNPX) from Buy to Hold.

Total
0
Shares
Related Posts
Read More

Bristol Myers Squibb Provides Update On RELATIVITY-123 Trial Evaluating The Fixed-Dose Combination Of Nivolumab And Relatlimab In Patients With Previously Treated Metastatic Microsatellite Stable Colorectal Cancer

Bristol Myers Squibb (NYSE:BMY) today announced that the Phase 3 RELATIVITY-123 trial evaluating the fixed-dose combination of nivolumab and relatlimab for the treatment of microsatellite stable (MSS) metastatic

BMY